Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SelvitaWAR:SLV -9.55%79 Gross Margin % is -0.53% as of Jun. 2026. GuruFocus rates WAR:SLV with a GF Score™ of 79/100 and a GF Value™ of zł47.93 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Selvita ranks better than 86.6% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Selvita's Gross Profit for the
three
months ended in Jun. 2026 was zł-0.4 Mil. Selvita's Revenue for the
three
months ended in Jun. 2026 was zł82.1 Mil. Therefore, Selvita's Gross Margin % for the quarter that ended in Jun. 2026 was -0.53%.
The historical rank and industry rank for Selvita's Gross Margin % or its related term are showing as below:
WAR:SLV'
s Gross Margin % Range Over the Past 10 Years
Min: 72.26 Med: 80.81 Max: 85.04
Current: 80.17
During the past 7 years, the highestGross Margin % of Selvita was 85.04%. The lowest was 72.26%. And the median was 80.81%.
WAR:SLV's Gross Margin % is ranked better than 86.6% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.825
vs WAR:SLV: 80.17
Selvita had a gross margin of -0.53% for the quarter that ended in Jun. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Selvita was -1.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Selvita had a gross margin of -0.53% for the quarter that ended in Jun. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Selvita Gross Margin % Related Terms
Selvita Gross Margin % Historical Data
* Premium members only.
The historical data trend for Selvita's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SLV vs TMO, DHR, NTRA: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Selvita's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Selvita Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Selvita's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Selvita's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Selvita (WAR:SLV) has a Gross Margin % of -0.53% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Selvita and its competitors. Over the past decade, Selvita's Gross Margin % has ranged from 72.26 to 85.04. According to the industry distribution chart, Selvita ranks #26 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 13.4%.
Is Selvita's Gross Margin % too high?
Selvita's current Gross Margin % is -0.53%. Over the past 10 years, this metric has ranged from a low of 72.26 to a high of 85.04. Based on the distribution chart, Selvita ranks #26 out of 194 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Selvita has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Selvita's Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Selvita ranks #26 out of 194 companies for Gross Margin %. This places Selvita in the top 13% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 50.83. Historically, Selvita's own Gross Margin % has ranged from 72.26 to 85.04 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.83, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Selvita and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Selvita's current Gross Margin % is -0.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selvita stock overvalued right now?
Based on GuruFocus' analysis, Selvita (WAR:SLV) is currently considered Significantly Undervalued. The stock's GF Value™ is zł47.93, compared to a current price of zł23.00 — trading 52% below its estimated fair value. The current Gross Margin % is -0.53%. Selvita's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Selvita (WAR:SLV), the current Gross Margin % is -0.53% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Selvita (WAR:SLV) Overvalued in 2026?
Based on GuruFocus' analysis, Selvita stock appears to be undervalued.
The current stock price of zł23.00 is trading 52% below its estimated GF Value™ of zł47.93.
GuruFocus considers Selvita to be Significantly Undervalued.
Key valuation signals for WAR:SLV:
Gross Margin %: -0.53%
GF Value™: zł47.93 vs. price of zł23.00 (52% below fair value)
No single metric tells the full story. See the WAR:SLV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Selvita SA is a Poland based parent company of Selvita Group is one of the largest preclinical contract research organizations in Europe. It also develops bioinformatics solutions supporting innovative projects at preclinical stages. It also provides services provided to external contractors are in the field of chemistry, analytics, regulatory, biochemistry and cell biology and also the integrated research and development projects.
79GF Score
Get the complete analysis for WAR:SLV
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SLV has been successfully added to your 
